Atara Biotherapeutics, Inc.
ATRA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $128,940 | $8,573 | $63,573 | $20,340 |
| % Growth | 1,404% | -86.5% | 212.6% | – |
| Cost of Goods Sold | $21,009 | $8,886 | $0 | $282,001 |
| Gross Profit | $107,931 | -$313 | $63,573 | -$261,661 |
| % Margin | 83.7% | -3.7% | 100% | -1,286.4% |
| R&D Expenses | $151,483 | $224,785 | $272,533 | $282,001 |
| G&A Expenses | $39,886 | $50,908 | $71,553 | $78,801 |
| SG&A Expenses | $39,886 | $50,908 | $71,553 | $78,801 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$282,001 |
| Operating Expenses | $191,369 | $275,693 | $344,086 | $78,801 |
| Operating Income | -$83,438 | -$276,006 | -$280,513 | -$340,462 |
| % Margin | -64.7% | -3,219.5% | -441.2% | -1,673.9% |
| Other Income/Exp. Net | -$1,977 | -$105 | $52,223 | $367 |
| Pre-Tax Income | -$85,415 | -$276,111 | -$228,290 | -$340,095 |
| Tax Expense | -$12 | $15 | $12 | $46 |
| Net Income | -$85,403 | -$276,126 | -$228,302 | -$340,141 |
| % Margin | -66.2% | -3,220.9% | -359.1% | -1,672.3% |
| EPS | -11.41 | -65.18 | -55.96 | -90.78 |
| % Growth | 82.5% | -16.5% | 38.4% | – |
| EPS Diluted | -11.41 | -65.18 | -55.96 | -90.78 |
| Weighted Avg Shares Out | 7,488 | 4,236 | 4,080 | 3,747 |
| Weighted Avg Shares Out Dil | 7,488 | 4,236 | 4,080 | 3,747 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,110 | $5,426 | $3,059 | $367 |
| Interest Expense | $4,615 | $5,285 | $373 | $0 |
| Depreciation & Amortization | $5,051 | $4,829 | $5,653 | $9,345 |
| EBITDA | -$75,749 | -$265,997 | -$222,264 | -$331,117 |
| % Margin | -58.7% | -3,102.7% | -349.6% | -1,627.9% |